**Recent developments center on the Trump administration’s accelerated push to move marijuana from Schedule I to Schedule III.** Following a December 2025 executive order directing expedited action, the Department of Justice issued a final order in late April 2026 that immediately rescheduled FDA-approved cannabis products and state-licensed medical marijuana to Schedule III under treaty authority, bypassing full notice-and-comment rulemaking. A parallel expedited DEA administrative hearing on broader rescheduling of all marijuana convened June 29–July 15, 2026; closing briefs were filed in August, with the DEA arguing in early September that marijuana no longer meets Schedule I criteria due to accepted medical use. On September 9, a federal appeals court denied opponents’ request for a stay, allowing proceedings to advance while an administrative law judge prepares a recommendation. These steps, combined with ongoing litigation and potential final agency action, shape trader assessments of timing and scope for complete rescheduling.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于$809,838 交易量
2026-12-31
9月30日
2%
12月31日
16%
$809,838 交易量
9月30日
$659 交易量
2%
12月31日
$199,608 交易量
16%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Recent developments center on the Trump administration’s accelerated push to move marijuana from Schedule I to Schedule III.** Following a December 2025 executive order directing expedited action, the Department of Justice issued a final order in late April 2026 that immediately rescheduled FDA-approved cannabis products and state-licensed medical marijuana to Schedule III under treaty authority, bypassing full notice-and-comment rulemaking. A parallel expedited DEA administrative hearing on broader rescheduling of all marijuana convened June 29–July 15, 2026; closing briefs were filed in August, with the DEA arguing in early September that marijuana no longer meets Schedule I criteria due to accepted medical use. On September 9, a federal appeals court denied opponents’ request for a stay, allowing proceedings to advance while an administrative law judge prepares a recommendation. These steps, combined with ongoing litigation and potential final agency action, shape trader assessments of timing and scope for complete rescheduling.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
市场开放时间： Feb 7, 2026, 5:04 PM ET
交易量
$809,838结束日期
2027-01-01市场开放时间
Feb 7, 2026, 5:04 PM ETThis market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Recent developments center on the Trump administration’s accelerated push to move marijuana from Schedule I to Schedule III.** Following a December 2025 executive order directing expedited action, the Department of Justice issued a final order in late April 2026 that immediately rescheduled FDA-approved cannabis products and state-licensed medical marijuana to Schedule III under treaty authority, bypassing full notice-and-comment rulemaking. A parallel expedited DEA administrative hearing on broader rescheduling of all marijuana convened June 29–July 15, 2026; closing briefs were filed in August, with the DEA arguing in early September that marijuana no longer meets Schedule I criteria due to accepted medical use. On September 9, a federal appeals court denied opponents’ request for a stay, allowing proceedings to advance while an administrative law judge prepares a recommendation. These steps, combined with ongoing litigation and potential final agency action, shape trader assessments of timing and scope for complete rescheduling.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
交易量
$809,838结束日期
2027-01-01市场开放时间
Feb 7, 2026, 5:04 PM ET**Recent developments center on the Trump administration’s accelerated push to move marijuana from Schedule I to Schedule III.** Following a December 2025 executive order directing expedited action, the Department of Justice issued a final order in late April 2026 that immediately rescheduled FDA-approved cannabis products and state-licensed medical marijuana to Schedule III under treaty authority, bypassing full notice-and-comment rulemaking. A parallel expedited DEA administrative hearing on broader rescheduling of all marijuana convened June 29–July 15, 2026; closing briefs were filed in August, with the DEA arguing in early September that marijuana no longer meets Schedule I criteria due to accepted medical use. On September 9, a federal appeals court denied opponents’ request for a stay, allowing proceedings to advance while an administrative law judge prepares a recommendation. These steps, combined with ongoing litigation and potential final agency action, shape trader assessments of timing and scope for complete rescheduling.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题